• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    23Andme Holding Co. (NQ: ME )

    0.4089 +0.0089 (+2.22%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,521,495
    Open 0.4000
    Bid (Size) 0.4060 (20)
    Ask (Size) 0.4199 (1)
    Prev. Close 0.4000
    Today's Range 0.3950 - 0.4249
    52wk Range 0.3500 - 2.030
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Looking Into 23andMe Holding's Recent Short Interest
    Via Benzinga
    3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
    Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
    Via InvestorPlace

    Performance

    YTD
    -54.99%
    -54.99%
    1 Month
    -25.19%
    -25.19%
    3 Month
    -13.18%
    -13.18%
    6 Month
    -57.12%
    -57.12%
    1 Year
    -75.59%
    -75.59%

    More News

    Read More
    23andMe Launches New Genetic Report on Bipolar Disorder
    From 23andMe, Inc.
    Via GlobeNewswire
    Why 23andMe Stock Tumbled 10% on Tuesday
    Via The Motley Fool
    23andMe and the Colorectal Cancer Alliance Collaborate to Help Advance Colorectal Cancer Research in the Black Community
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting
    From 23andMe, Inc.
    Via GlobeNewswire
    Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history
    From 23andMe, Inc.
    Via GlobeNewswire
    ME Stock Earnings: 23andMe Holding Beats EPS, Beats Revenue for Q4 2024
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals
    From 23andMe, Inc.
    Via GlobeNewswire
    23andMe to Report Q4 and Full Year FY2024 Financial Results
    From 23andMe, Inc.
    Via GlobeNewswire
    Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case
    From Potter Handy LLP
    Via Business Wire
    23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    From 23andMe, Inc.
    Via GlobeNewswire
    This Technology Company Is Being Acquired at a Shocking 207% Premium -- and These 2 Stocks Could Be Next
    Via The Motley Fool
    Nasdaq Down 0.5%; Lithium Americas Shares Slide
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
    Via Benzinga
    Exposures Fossil Fuels
    Once Valued At Billions, 23andMe's CEO Considers Privatization To Secure Company's Future
    Via Benzinga
    Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Is Lithium Americas (LAC) Stock Down 28% Today?
    Via InvestorPlace
    Walgreens Layoffs 2024: What to Know About the Latest WBA Job Cuts
    Via InvestorPlace
    Topics Workforce
    Exposures Layoff
    ME Stock Alert: CEO Anne Wojcicki Seeks to Save 23andMe in Take-Private Deal
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    23andMe announces CEO’s intention to pursue a potential take-private
    From 23andMe, Inc.
    Via GlobeNewswire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.